Antibody-drug conjugates can deliver chemotherapy directly to tumors but more than 95 percent of the dose often ends up in healthy tissues, decreasing efficacy and increasing toxicity. Mythic Therapeutics FateControl technology improves the uptake of ADCs in cancerous cells while avoiding the release of their toxic payloads in healthy ones. This promises to increase efficacy of these therapies in a wide range of cancers without causing unacceptable side-effects. We spoke to Brian Fiske, co-founder, chief scientific officer of Mythic, about the challenges that have held back the benefits of ADCs, how the company’s FateControl technology addresses those, and how it is thinking of building a pipeline of ADCs across indications.
Using Technology to Regain Abilities after Spinal Cord Injury
Why Drug Developers Have a Growing Interest in Targeting Mitochondria
Beefing Up Computational Muscle to Understand Molecular Activity of Drug Candidates
Targeting a Multitude of CIN in Cancer Cells
The Year in Biotech and What’s Ahead in 2024
Transforming Healthcare with Data
Realizing the Promise of IL-2 Therapies with AI
Unlocking Real-World Data to Improve Outcomes
A Silicon Valley Entrepreneur Investing at the Intersection of Tech and Biotech
A Company Betting Its Physics-Based AI Will Fuel a Quantum Leap in Drug Discovery
Detecting Alzheimer’s Disease Early through a Blood Test
Addressing Supply-Chain Challenges Underlying Drug Shortages with Synthetic Biology
Building Better and More Affordable Vaccines
Overcoming Resistance to Targeted Therapies
Using Tumor Gene Therapy to Overcome Barriers to Immunotherapies
Using AI to Generate Mini-Protein Therapeutics
Inhibiting Cell Death to Preserve Vision in Retinal Diseases
Leveraging Generative AI to Design Therapeutic Antibodies
Managing Pain without Addiction
Using AI to Match Cancer Patients to their Best Treatment Options
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
Ground Truths